Eversense PASS, a payment assistance and simple savings program, aims to enhance affordability and access to Eversense E3. Ascensia serves as the global commercial partner for Senseonics. The Senseonics continuous glucose monitor (CGM), a 180-day implantable CGM, received FDA approval in February of last year.
It features a third-generation sensor with SBA technology that enhances sensor longevity. This makes it — according to Senseonics — the longest-lasting CGM system. The fully implantable sensor requires just two insertion and removal procedures per year.
About the enhanced program
The new and improved program provides more people with diabetes eligibility for assistance paying for the system. That includes increased savings for eligible first-time users.
Ascensia created Eversense PASS in April 2022. It now expands eligibility to all commercially insured people with diabetes across the U.S. That even includes those who don’t have coverage for Eversense E3 from their insurance provider.
New Eversense E3 users now only pay $99 out of pocket for their first two E3 systems. That extends the $99 introductory offer previously available for just the initial sensor and smart transmitter. Out-of-pocket costs now total less than $200 for an entire year of CGM use for new users, Ascensia said. For each sensor thereafter, users pay a maximum of $100 per month (or $600 for the six-month duration of each sensor).
“We’ve been working to ensure that as many people as possible can have access to this unique product,” said Rudy Thoms, VP, CGM Commercial U.S. of Ascensia Diabetes Care. “Alongside our partner Senseonics, we know the positive impact that Eversense E3 can have on the lives of people with diabetes and that’s one of many reasons why we are pleased to extend the savings and eligibility for Eversense PASS. Although most major insurers now cover Eversense E3 CGM System, we are also proud to offer these savings regardless of coverage, so that no one with commercial insurance is left behind.”
